Report on the Custody, Management, and Use of Raised Funds for 2025
To the Shareholders of Shu Tai Shen (Beijing) Biopharmaceutical Co., Ltd.:
We have been engaged to perform a special audit on the "Report on the Custody, Management, and Use of Raised Funds for 2025" prepared by the Board of Directors of Shu Tai Shen (Beijing) Biopharmaceutical Co., Ltd. (hereinafter referred to as "the Company") as of December 31, 2025.
I. Responsibilities of the Board of Directors
The Company's Board of Directors is responsible for preparing the "Report on the Custody, Management, and Use of Raised Funds for 2025" in accordance with the "Supervisory Rules for Raised Funds of Listed Companies" issued by the China Securities Regulatory Commission, the "Shenzhen Stock Exchange Listed Companies Self-Regulatory Supervision Guidelines No. 2 - Normative Operation of GEM Companies," and the "Shenzhen Stock Exchange GEM Company Self-Regulatory Supervision Guidelines No. 2 - Announcement Format." This responsibility includes ensuring the content is true, accurate, and complete, and free from false records, misleading statements, or material omissions.
II. Responsibilities of the Certified Public Accountants
Our responsibility is to express an opinion on the "Report on the Custody, Management, and Use of Raised Funds for 2025" based on our audit work.
III. Overview of Work
We performed our audit in accordance with the "Other Assurance Services Practice Standards for Chinese Certified Public Accountants No. 3101 - Assurance Services Other Than Audits or Reviews of Historical Financial Information." This standard requires us to comply with professional ethics, plan, and execute our audit to obtain reasonable assurance that the "Report on the Custody, Management, and Use of Raised Funds for 2025" is free from material misstatement. Our audit procedures included examining accounting records, recalculating relevant figures, and other procedures we deemed necessary. We believe that our audit provides a reasonable basis for our opinion.
IV. Audit Conclusion
We are of the opinion that the "Report on the Custody, Management, and Use of Raised Funds for 2025" prepared by the Company's Board of Directors is, in all material respects, compiled in accordance with the aforementioned "Supervisory Rules for Raised Funds of Listed Companies" and the relevant regulations of the stock exchange. It fairly reflects the custody, management, and use of the Company's raised funds for 2025 in all material respects.
Tianheng Certified Public Accountants (Special General Partnership)
Certified Public Accountant: Kan Zhongsheng
China · Nanjing April 26, 2026
Certified Public Accountant: Xue Feixia
Report of the Board of Directors of Shu Tai Shen (Beijing) Biopharmaceutical Co., Ltd. on the Custody, Management, and Use of Raised Funds for 2025
The Company and all members of its Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or material omissions.
In accordance with the "Supervisory Rules for Raised Funds of Listed Companies," the "Shenzhen Stock Exchange Listed Companies Self-Regulatory Supervision Guidelines No. 2 - Normative Operation of GEM Companies," and the Company's "Raised Funds Management System," this report outlines the custody, management, and use of raised funds by Shu Tai Shen (Beijing) Biopharmaceutical Co., Ltd. (hereinafter referred to as "the Company" or "the Company") for 2025.
I. Basic Information on Raised Funds
(I) Amount of Funds Raised and Time of Receipt